Eli Lilly is trying to make that routine feel less like a chore
CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg.2 If approved, CagriSema would become the first injectable GLP-1 receptor agonist and amylin analogue combination treatment
"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA 2021 (STEP 4 withdrawal study) Jastreboff AM, et al
Cofactors: Magnesium, Vitamin B6, Glycine, Glutamic Acid, Selenium, Vitamin B2 (riboflavin), Molybdenum
In terms of being an evidence-backed treatment thats proven to work, the receipts arent there yet for ipamorelin
Its critical to provide clear, honest information about what these drugs can and cannot do